Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test

Psychopharmacology

Volumn 136, Issue 2, 1998, Pages 190-197

  Rénéric, Jean Philippe ^a,b   Lucki, Irwin ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CNRS   (France)

Author keywords

Antidepressant; Behavior; Desipramine; Dopamine; Duloxetine; Fluoxetine; Forced swimming; Milnacipran; Norepinephrine; Serotonin; Ven lafaxine

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; DESIPRAMINE; DULOXETINE; FLUOXETINE; MILNACIPRAN; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CLIMBING; DEPRESSION; DOPAMINE METABOLISM; DOSE RESPONSE; DRUG MECHANISM; INHIBITION KINETICS; MALE; MONOAMINE RELEASE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; SWIMMING;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BUPROPION; CYCLOPROPANES; DESIPRAMINE; FLUOXETINE; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; THIOPHENES;

EID: 0031931974     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050555     Document Type: Article

References (42)

1. Ansseau M, von Frenckell R, Mertens C, De Wilde J, Botte L, Devoitille JM, Evrard JL, De Nayer A, Darimont P, Dejaiffe G, Mirel J, Meurice E, Parent M, Couzinier JP, Demarez JP, Serre C (1989) Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients. Psychopharmacology 98:163-168
2. Artigas F (1995) Selective serotonin noradrenaline reuptake inhibitors (SNRIs) Pharmacology and therapeutic potential in the treatment of depressive disorders. CNS Drugs 4:79-89
3. Aston-Jones G, Shipley MT, Chouvet G, Ennis M, van Bockstaele V, Pieribone V, Shiekhatter R, Akaoka H, Drolet G, Astier P, Charlety P, Valentino RJ, Williams JT (1991) Afferent regulation of locus coeruleus neurons: anatomy, physiology and pharmacology. Prog Brain Res 88:47-76
4. Bel N, Artigas F (1996) In vivo effects of the simultaneous blockade of serotonin and norepinephrine transporters on serotonergic function. Microdialysis studies. J Pharmacol Exp Ther 278:1064-1072
5. Bergstrom RF, Peyton AL, Lemberger L (1992) Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 51:239-248
6. Blier P, de Montigny C, Chaput Y (1990) A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J Clin Psychiatry 51[4, Suppl]:14-20
7. Borsini F, Meli A (1988) Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology 94:147-160
8. Caldecott-Hazard S, Morgan D G, DeLeon-Jones F, Overstreet D H, Janowsky D (1991) Clinical and biochemical aspects of depressive disorders: II. Transmitter/receptor theories. Synapse 9:251-301
9. Chen NH, Reith MEA (1994) Effects of locally applied cocaine, lidocaine, and various uptake blockers on monoamine transmission in the ventral tegmental area of freely moving rats: a microdialysis study of monoamine interrelationships. J Neurochem 63: 1701-1713
10. Cooper BR, Wang CM, Cox RF, Norton R, Shea V, Ferris RM (1994) Evidence that the acute behavioral and electrophysiological effects of bupropion(Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 11: 133-141
11. Darmani NA (1994) The effects of acute cocaine administration on the DOI-induced head-twitch response in reserpinized mice. Pharmacol Biochem Behav 49:229-232
12. 2A receptor response. Pharmacol Biochem Behav 49:229-232
13. Delgado PL, Price LH, Miller HL, Salomon RM, Licinio J, Krystal JH, Heninger GR, Charney DS (1991) Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression. Psychopharmacol Bull 27:321-330
14. Delgado PL, Miller HL, Salomon RM, Licinio J, Heninger GR, Gelenberg AJ, Charney DS (1993) Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull 29:389-396
15. Derivan A, Entsuah AR, Kikta D (1995) Venlafaxine: measuring the onset of antidepressant action. Psychopharmacol Bull 31:439-447
16. Detke MJ, Lucki I (1996) Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test: the effects of water depth. Behav Brain Res 73:43-46
17. Detke MJ, Rickels M, Lucki I (1995) Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 121:66-72
18. Engleman EA, Perry KW, Wong DT (1995) Simultaneous increase of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacology 12:287-295
19. Hemby SE, Lucki I, Gatto G, Singh A, Thonley C, Matasi J, Kong N, Smith JE, Davies HML, Dworkin SI (1997) Potential antidepressant effects of novel tropane compounds selective for serotonin or dopamine transporters. J Pharmacol Exp Ther 282:727-733
20. Holliday SM, Benfield P (1995) Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 49: 280-294
21. Katz MM, Maas JW, Frazer A, Koslow SH, Bowden CL, Berman N, Swann AC, Stokes PE (1994) Drug-induced actions on brain neurotransmitter systems and changes in the behaviors and emotions of depressed patients. Neuropsychopharmacology 11:89-100
22. Macher JP, Sichel JP, Serre C, von Frenkell R, Huck JC, Demarez JP (1989) Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders. Neuropsychobiology 22:77-82
23. Marshall RD, Liebowitz MR (1996) Paroxetine/bupropion combination treatment for refractory depression. J Clin Psychopharmacol 16:80-81
24. Mendels J, Johnston R, Mattes J, Riesenberg R (1993) Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol Bull 29:169-174
25. Mongeau R, Blier P, de Montigny C (1993) In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of alpha-2-adrenoceptors on 5-hydroxytrypamine terminals in the rat hippocampus. Naunyn-Schmiedeberg's Arch Pharmacol 347:266-272
26. Moret C, Charveron M, Finberg JP, Couzinier JP, Briley M (1985) Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 24:1211-1219
27. Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, Sigg EB (1986) Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 35:4493-4497
28. Nelson, JC, Mazure CM, Bowers MB, Jatlow PI (1991) A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 48:303-307
29. Porsolt RD (1981) Behavioral despair. In: Enna SJ (ed) Antidepressants: neurochemical, behavioral and clinical perspectives. Raven Press, New York, pp 121-139
30. Porsolt RD, Le Pichon M, Jalfre M (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature 266:730-732
31. Porsolt RD, Anton G, Deniel M, Jalfre M (1978) Behavioral despair in rats: A new model sensitive to antidepressant treatments. Eur J Pharmacol 47:379-391
32. Schweizer E, Weise C, Clary C, Fox I, Rickels K (1991) Placebo-controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol 11:233-236
33. Schweizer E, Feighner J, Mandos LA, Rickels K (1994) Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 55: 104-108
34. Serre C, Clerc G, Escande M, Feline A, Ginestet D, Tignol J, van Amerongen P (1986) An early clinical trial of midalcipran. 1. Phenyl-1-diethyl aminocarbonyl-2-aminomethyl cyclopropane (Z) hidrochloride, a potential fourth generation antidepressant. Curr Ther Res 39:156-164
35. Seth R, Jennings AL, Bindman J, Phillips J, Bergmann K (1992) Combination treatment with noradrenaline and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 161:562-565
36. 2-Adrenoceptor modulation of rat ventral hippocampal 5-hydroxytryptamine release in vivo. Naunyn-Schmiedeberg's Arch Pharmacol 345:137-143
37. Vandermaelen CP, Aghajanian GK (1983) Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices. Brain Res 289:109-113
38. Vaughan DA (1988) Interaction of fluoxetine with tricyclic antidepressants. Am J Psychiatry 145:1478
39. Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS, Pollack MH, Kelly K (1989) Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 50:447-449
40. 1A agonists measured with the forced swim test. Psychopharmacology 101:497-504
41. Wilens TE, Biederman J, Baldessarini RJ, McDermott SP, Puopolo PR, Flood JG (1992) Fluoxetine inhibits desipramine metabolism. Arch Gen Psychiatry 49:752
42. Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, Robertson DW (1993) LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 8: 23-33